Clinical Trials
98 trialsTRACK
TargetCancer Foundation
A Prospective Study Using Implanted Fiducial Markers to Assess Treatment Accuracy and Esophageal Toxicity in Spinal Stereotactic Body Radiation Therapy
M.D. Anderson Cancer Center
SHERLOCK
University Health Network, Toronto
iCaRe2
University of Nebraska
CUPem
Imperial College London
PaCIFiC-CUP Classifies Cancer of Unknown Primary
Sun Yat-sen University
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
M.D. Anderson Cancer Center
A Phase 2a, Single-dose, Open-label Study to Evaluate Diagnostic Performance and Safety of Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer, in Patients With Unknown Primary Head and Neck Cancer (ILLUMINATE STUDY)
University of Texas Southwestern Medical Center
Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
National Cancer Institute (NCI)
TraveraRTGx
Travera Inc
Cancer Genetic Testing in Ethnic Populations
Mayo Clinic
EGGCUP
The Christie NHS Foundation Trust
Sintilimab in Cancer of Unknown Primary
M.D. Anderson Cancer Center
FAPI PET RDRC
Jonsson Comprehensive Cancer Center
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
M.D. Anderson Cancer Center
18F-FAPI PET in Cancers of Unknown Primary Site
First Affiliated Hospital of Zhejiang University
NorCUP
Haukeland University Hospital
IMPACT
University Health Network, Toronto
CUPISCO
Hoffmann-La Roche
CAPTIV-8
British Columbia Cancer Agency
Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor
Merus B.V.
CUP
AHS Cancer Control Alberta
Genomic Testing and Resulting Medical Decisions
Arbeitsgemeinschaft medikamentoese Tumortherapie
ACROPOLI
SOLTI Breast Cancer Research Group
GENIUS
University Health Network, Toronto
ROOT
Taproot Health
SIRIUS
Munich Leukemia Laboratory
OCTANE
University Health Network, Toronto
Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs
Travera Inc
VISIONARY
Peking University
CUP-COMP
The Christie NHS Foundation Trust
OP-CUP
Rigshospitalet, Denmark
HARE-40
University of Southampton
AGNOSTOS
Fondazione del Piemonte per l'Oncologia
REFLECT
University Medical Center Groningen
Pro-Active Genetic Testing in Patients With Solid Tumors, Inherit Study
Mayo Clinic
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced or Refractory Solid Tumors
Eastern Cooperative Oncology Group
TOFFEE
University of Edinburgh
FAPI-CUP
Peter MacCallum Cancer Centre, Australia
Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS
Rigshospitalet, Denmark
PUTNET
Excel Diagnostics and Nuclear Oncology Center
APL-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors
Apollomics (Australia) Pty. Ltd.
Tissue-of-origin Directing Therapy in Patients With Cancer of Unknown Primary
Fudan University
Real World Study of Diagnosis and First-line Treatment Among Patients With Cancer of Unknown Primary in China
Fudan University
Antineoplaston Therapy in Treating Patients With Cancer of Unknown Primary Origin
Burzynski Research Institute
PIONEER
SpeciCare
Gemcitabine in Treating Patients With Metastatic Cancer of Unknown Primary
Eastern Cooperative Oncology Group
Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
University of Chicago
CheCUP
University Hospital Heidelberg